source
- FDA approves Isembyld, first therapy to target muscle loss in SMA patientsScholar Rock received FDA approval for Isembyld, the first drug designed to address muscle loss in spinal muscular atrophy (SMA). The approval covers adults and children aged two years and older w…
- Cullinan and Taiho report six-month survival gain for EGFR exon 20 NSCLC in phase 3 trialCullinan Therapeutics and Taiho Oncology presented interim data from their phase 3 Rezilient3 study, which evaluated the tyrosine kinase inhibitor zipalertinib combined with platinum‑based chemothe…